Dr. Martens (LON:DOCS) Stock Price Up 2.6% – Should You Buy?

Dr. Martens plc (LON:DOCS) shares traded up 2.6% during trading on Wednesday. The company traded as high as GBX 68.30 and last traded at GBX 67.90. 993,706 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 6,513,325 shares. The stock had previously closed at GBX 66.20.

Wall Street Analyst Weigh In

Separately, Berenberg Bank restated a “buy” rating and set a GBX 110 target price on shares of Dr. Martens in a research note on Friday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Stock Performance

The company has a market cap of £650.88 million, a PE ratio of 28.33, a PEG ratio of 6.40 and a beta of 0.26. The stock has a 50 day simple moving average of GBX 74.43 and a two-hundred day simple moving average of GBX 70.86. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.